Qurocel’s Anbalcabtagene Autoleucel (Rimcato) Receives Reimbursement Approval for Cancer Treatment in South Korea
South Korea’s first domestically developed CAR-T cell therapy, Curonix’s “Anbal-cel” (anbalcabtagene autoleucel), has moved one step closer to national health insurance coverage. The Health Insurance Review and Assessment Service (HIRA) recently reached a decision regarding the reimbursement criteria for the treatment, marking a significant milestone for patients battling specific blood cancers in South Korea. The … Read more